Suzhou Basecare Medical Corporation Limited (2170.HK) Stock

About Suzhou Basecare Medical Corporation Limited

Suzhou Basecare Medical Corporation Limited, an investment holding company provides genetic testing solutions for assisted human reproduction in the People's Republic of China and Australia. The company offers pre-implantation genetic test kits, including PGT-A kit to detect aneuploidy; PGT-M kit to detect single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kit to detect chromosome structural rearrangements, which are common causes of recurrent miscarriage, implantation failures, and birth defects. It also provides DA500, a high-throughput gene sequencer that provides users with sequencing options; DA5000 high-throughput gene sequencer which provides one-stop genetic laboratory solution for assisted reproductive centers; BS1000C, a high-throughput automated sample preparation system; PGT-A, PGT-M, and PGT-SR analysis software; Geri, a Time-Lapse Incubator to provide safe and stable culture conditions for embryo culturing; and Gems, a range of assisted reproductive laboratories fluids. In addition, the company offers BCT38, a liquid nitrogen storage dewar with a digital management system; BSG800A and BSG800C, a cryopreservation system; BKA210, a Sperm quality analyzer; Self Sperm Testing Device; Gavi, an automated vitrification instrument for the process of freezing embryos and eggs in the IVF automated vitrification; Intelligent assisted reproduction management system (iARMS), an assisted reproduction management system that runs through the reproductive cycle and covers patient medical records, medical diagnosis, and treatment plans. Further, it provides marketing services; and engages in the research and development of testing devices, instruments and consumables, as well as software for testing devices and instruments. The company serves hospitals and reproductive clinics. It sells its products through distributors. Suzhou Basecare Medical Corporation Limited was incorporated in 2010 and is headquartered in Suzhou, China.

Suzhou Basecare Medical Corporation Limited (2170.HK) stock trades at $1.40 with a market capitalization of $381.57M. The stock is valued at a price-to-earnings (P/E) ratio of -1.51, price-to-book of 0.35, price-to-sales of 1.64. Over the past 52 weeks the stock has ranged between $1.23 and $4.36, and currently trades 67.9% below its 52-week high.

On profitability, Suzhou Basecare Medical Corporation Limited generates a return on equity (ROE) of -21.52%, an operating margin of -62.41%, a net profit margin of -95.79%.

Official website: www.basecare.cn